Zeroing in on a skin cancer vaccine
It's been 20 years since Australian researchers created the world's first vaccine developed specifically to prevent cancer.
Thanks to the HPV vaccine, Australia is on track to become
one of the first nations in the world to eliminate cervical cancer.
Now, research led by scientists Down Under has made another
breakthrough – this time for skin cancer.
The first personalized mRNA cancer vaccine has now succeeded
in a phase 3 clinical trial, reducing the risk of melanoma returning or causing
death by 42 percent compared with standard immunotherapy alone.
The results are even
better than scientists were expecting.
The global principal investigator, medical oncologist
Georgina Long from Melanoma Institute Australia (MIA), presented the results at
the European Society for Medical Oncology Congress 2026.
They are set to be published in the New England Journal
of Medicine.
